关于成年低级结质瘤分子生物标志物的最新进展和未来前景
Jessica L Fleming1, Arnab Chakravarti
1From the Department of Radiation Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH.
Cancer journal (Sudbury, Mass.)
|January 22, 2025
概括
最近关于质瘤分类和临床试验的更新正在改善患者的诊断和治疗. 本综述总结了低级质瘤的关键分子生物标志物,并讨论了未来的研究方向.
科学领域:
- 神经瘤学神经瘤学
- 分子诊断学 分子诊断学
- 临床试验结果 临床试验结果
背景情况:
- 2021年世界卫生组织分类更新了低级质瘤的诊断.
- 第三阶段临床试验的长期结果为治疗疗效提供了新的见解.
- 准确的诊断和有针对性的治疗对于管理较低级别质瘤至关重要.
研究的目的:
- 为成人低级质瘤提供分子生物标志物的综合摘要.
- 讨论这些患者的临床管理当前的挑战.
- 突出未来研究的潜力,以推进质瘤护理.
主要方法:
- 关于较低级别质瘤的最新文献的审查.
- 分析更新的分类系统 (世卫组织2021年).
- 从随机的III期临床试验中综合发现.
主要成果:
- 确定低度质瘤的强大可靠的分子生物标志物.
- 了解新分类如何影响患者管理.
- 认识到诊断和治疗分层的现有挑战.
结论:
- 质瘤管理的范式转变需要专注于分子生物标志物.
- 未来的相关生物学研究和技术进步是克服当前挑战的关键.
- 个性化治疗策略对于低度质瘤患者来说变得越来越重要.
相关概念视频
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...


